These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25759104)

  • 1. Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
    Amsallem M; Manzo-Silberman S; Dillinger JG; Sideris G; Voicu S; Bal dit Sollier C; Drouet L; Henry P
    Am J Cardiol; 2015 May; 115(9):1305-10. PubMed ID: 25759104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
    Siller-Matula JM; Delle-Karth G; Christ G; Neunteufl T; Maurer G; Huber K; Tolios A; Drucker C; Jilma B
    Int J Cardiol; 2013 Jul; 167(2):430-5. PubMed ID: 22305813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment.
    Becatti M; Fiorillo C; Gori AM; Marcucci R; Paniccia R; Giusti B; Violi F; Pignatelli P; Gensini GF; Abbate R
    Atherosclerosis; 2013 Dec; 231(2):392-400. PubMed ID: 24267257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Angiolillo DJ; Bernardo E; Sabaté M; Jimenez-Quevedo P; Costa MA; Palazuelos J; Hernández-Antolin R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Guzman LA; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2007 Oct; 50(16):1541-7. PubMed ID: 17936152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
    Bliden KP; Tantry US; Storey RF; Jeong YH; Gesheff M; Wei C; Gurbel PA
    Am Heart J; 2011 Jul; 162(1):160-5. PubMed ID: 21742103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Dillinger JG; Saeed A; Spagnoli V; Sollier CB; Sideris G; Silberman SM; Voicu S; Drouet L; Henry P
    Thromb Res; 2016 Aug; 144():56-61. PubMed ID: 27289074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
    J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
    Woo KS; Kim BR; Kim JE; Goh RY; Yu LH; Kim MH; Han JY
    Korean J Lab Med; 2010 Oct; 30(5):460-8. PubMed ID: 20890076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
    Dillinger JG; Drissa A; Sideris G; Bal dit Sollier C; Voicu S; Manzo Silberman S; Logeart D; Drouet L; Henry P
    Am Heart J; 2012 Oct; 164(4):600-606.e1. PubMed ID: 23067920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry.
    Gerotziafas GT; Zarifis J; Bandi A; Mossialos L; Galea V; Tsinopoulos G; Chaari M; Baccouche H; Sassi M; Elalamy I
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):356-63. PubMed ID: 22311629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
    Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
    Sarafoff N; Martischnig A; Wealer J; Mayer K; Mehilli J; Sibbing D; Kastrati A
    J Am Coll Cardiol; 2013 May; 61(20):2060-6. PubMed ID: 23524219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
    Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
    Bernlochner I; Jaitner J; Fries V; Dommasch M; Mayer K; Ott I; Langwieser N; Fusaro M; Laugwitz KL; Kastrati A; Ibrahim T
    Vasa; 2016; 45(2):155-61. PubMed ID: 27058802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.
    Peace AJ; Tedesco AF; Foley DP; Dicker P; Berndt MC; Kenny D
    J Thromb Haemost; 2008 Dec; 6(12):2027-34. PubMed ID: 18823340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.